Coya Therapeutics was founded by Dr. Howard Berman, a seasoned biotechnology entrepreneur and life science executive. He established the clinical-stage biopharmaceutical enterprise by merging early-stage research concepts with innovative regulatory T cell (Treg) modulation platforms, subsequently guiding the company through its initial public offering and early clinical pipeline milestones before transitioning to executive leadership and board roles.